• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
APRE

APRE

Aprea Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.76

-0.00 (-0.29%)

Rating:B-

Company Profile

CEO

Oren Gilad

IPO Date

2019-10-03

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.77

Prev. Close

$0.76

Day Low

$0.71

Day High

$0.78

52W Low

$0.55

52W High

$2.22

Market Cap

$0.00B

Volume

0.12M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

41.1%

Avg Negative

17.6%

Avg Neutral

41.4%

News Feed

Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations

GlobeNewsWire·8/12/2021·↑ positive

Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study

Benzinga·8/12/2021·↓ negative

Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program

GlobeNewsWire
·8/12/2021
·↓ negative

Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials

Benzinga·8/6/2021·↑ positive

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

GlobeNewsWire·8/5/2021·↓ negative

Implied Volatility Surging for Aprea (APRE) Stock Options

Zacks Investment Research·6/18/2021·↓ negative

Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

Zacks Investment Research·6/17/2021·↑ positive

Karolinska Development's portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia

GlobeNewsWire·6/17/2021·↑ positive

APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today

InvestorPlace·6/16/2021·↑ positive

APRE Stock Price Increases Over 40%: Why It Happened

Pulse2·6/16/2021·↑ positive